Skip to content

The effect of Levetiracetam on the treatment of positive and negative symptoms of schizophrenia

The effect of adding Levetiracetam to antipsychotic therapy in reducing positive and negative symptoms in schizophrenia patients admitted to Razi Psychiatric Center

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20221108056437N1
Enrollment
70
Registered
2023-08-25
Start date
2023-07-21
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention groupIn the daily intervention group, Levetiracetam is prescribed in a dose of 1000 mg daily. It started with a dose of 250 mg 2 times a day for 2 weeks and increased to 5

Sponsors

University of social welfare and rehabilitation sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Schizophrenia diagnosis by a psychiatrist The occurrence of positive and negative symptoms in the symptoms of the disorder based on the Scale of positive and negative symptoms of schizophrenia The absence of other mental disorders at the same time, based on the psychiatrist's diagnosis, medical records and interview with the patient The absence of mental retardation or chronic diseases such as epilepsy, according to the psychiatrist's diagnosis .Not having in the type of drugs used

Exclusion criteria

Exclusion criteria: Schizophrenia diagnosis by a psychiatrist in patients admitted to Razi Hospital in a certain period of time Not suffering from other mental illnesses such as mental retardation Not suffering from a chronic physical disease such as epilepsy

Design outcomes

Primary

MeasureTime frame
The score of positive and negative symptoms of schizophrenia in positive and negative syndrom scale questionnaire. Timepoint: Investigating the positive and negative symptoms of schizophrenia at the beginning of the study and 6 weeks after starting levetiracetam. Method of measurement: Positive and negative syndrom scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegin Zangenehnia

University of social welfare and rehabilitation sciences

drneginzangenehnia@gmail.com+98 21 4461 5382

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026